Transcriptional down-regulation of thromboxane A2 receptor expression via activation of MAPK ERK1/2, p38/NF-κB pathways

Journal of Vascular Research

Volumn 46, Issue 2, 2009, Pages 162-174

  Zhang, Wei ^a,b,c   Zhang, Yaping ^a,b   Edvinsson, Lars ^a,b   Xu, Cang Bao ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Mesenteric artery; Rat; Thromboxane A2 receptors; Vascular diseases

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; DACTINOMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2 RECEPTOR;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL MODEL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MESENTERIC ARTERY; MYOGRAPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT; TRANSCRIPTION REGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; MALE; MESENTERIC ARTERIES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; NF-KAPPA B; NITRIC OXIDE SYNTHASE; NUCLEIC ACID SYNTHESIS INHIBITORS; ORGAN CULTURE TECHNIQUES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTAGLANDIN ANTAGONISTS; PROTEIN KINASE INHIBITORS; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; RNA STABILITY; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION, GENETIC; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 50649118327     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000153247     Document Type: Article

References (60)

1. Narumiya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-1226.
2. Narumiya S, FitzGerald GA: Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001;108:25-30.
3. Huang JS, Ramamurthy SK, Lin X, Le Breton GC: Cell signalling through thromboxane A2 receptors. Cell Signal 2004;16:521-533.
4. Thomas DW, Mannon RB, Mannon PJ, Latour A, Oliver JA, Hoffman M, Smithies O, Koller BH, Coffman TM: Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 1998;102:1994-2001.
5. Radomski M: The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists. Acta Physiol Pol 1985;36:153-164.
6. Cockerham C, Webb ML, Hedberg SA, Runge MS: Regulation of the rat aortic smooth muscle cell thromboxane A2 receptor. Trans Assoc Am Physicians 1991;104:173-180.
7. Sachinidis A, Flesch M, Ko Y, Schror K, Bohm M, Dusing R, Vetter H: Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension 1995;26:771-780.
8. 1 receptor antagonist losartan. Br J Pharmacol 2001;134:1385-1392.
9. Geoffroy J, Benzoni D, Sassard J: Antihypertensive effect of thromboxane A2 receptor blockade in genetically hypertensive rats of the lyon strain. J Hypertens Suppl 1989;7:S272-S273.
10. Sugawara A, Uruno A, Kudo M, Ikeda Y, Sato K, Taniyama Y, Ito S, Takeuchi K: Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with sp1 in vascular smooth muscle cells. J Biol Chem 2002;277:9676-9683.
11. Uruno A, Sugawara A, Kudo M, Sato M, Sato K, Ito S, Takeuchi K: Transcription suppression of thromboxane receptor gene expression by retinoids in vascular smooth muscle cells. Hypertens Res 2003;26:815-821.
12. Dorn GW 2nd, Becker MW: Growth factors downregulate vascular smooth muscle thromboxane receptors independent of cell growth. Am J Physiol 1992;262:C927-C933.
13. Morinelli TA, Tempel GE, Jaffa AA, Silva RH, Naka M, Folger W, Halushka PV: Thromboxane A2/prostaglandin H2 receptors in streptozotocin-induced diabetes: effects of insulin therapy in the rat. Prostaglandins 1993;45:427-438.
14. Wilkes BM, Mento PF, Hollander AM: Reduced thromboxane receptor affinity and vasoconstrictor responses in placentae from diabetic pregnancies. Placenta 1994;15:845-855.
15. Davidge ST, Zhang Y: Estrogen replacement suppresses a prostaglandin h synthase-dependent vasoconstrictor in rat mesenteric arteries. Circ Res 1998;83:388-395.
16. Raines EW, Ross R: Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 1993;69:S30-S37.
17. Adner M, Cantera L, Ehlert F, Nilsson L, Edvinsson L: Plasticity of contractile endothelin-B receptors in human arteries after organ culture. Br J Pharmacol 1996;119:1159-1166.
18. Wackenfors A, Emilson M, Ingemansson R, Hortobagyi T, Szok D, Tajti J, Vecsei L, Edvinsson L, Malmsjo M: Ischemic heart disease induces upregulation of endothelin receptor mRNA in human coronary arteries. Eur J Pharmacol 2004;484:103-109.
19. Luo G, Xu CB, Cao YX, Edvinsson L: Transcriptional up-regulation in expression of 5-hydroxytryptamine 2A and transcriptional down-regulation of angiotensin II type 1 receptors during organ culture of rat mesenteric artery. Basic Clin Pharmacol Toxicol 2004;95:280-287.
20. Cao YX, He LC, Xu CB, Luo GG, Edvinsson L: Enhanced transcription of contractile 5-hydroxytryptamine 2A receptors via extracellular signal-regulated kinase 1/2 after organ culture of rat mesenteric artery. Basic Clin Pharmacol Toxicol 2005;96:282-288.
21. 1B/1D receptors during organ culture of cerebral arteries. Neuroreport 2001;12:1605-1608.
22. Hansen-Schwartz J, Svensson CL, Xu CB, Edvinsson L: Protein kinase mediated upregulation of endothelin A, endothelin B and 5-hydroxytryptamine 1B/1D receptors during organ culture in rat basilar artery. Br J Pharmacol 2002;137:118-126.
23. B receptor upregulation in rat mesenteric arteries. Eur J Pharmacol 2002;454:209-215.
24. B receptor-mediated vasoconstriction in rat coronary artery after organ culture. Eur J Pharmacol 2006;539:192-194.
25. B receptors in rat. Stroke 2002;33:2311-2316.
26. Vikman P, Edvinsson L: Gene expression profiling in the human middle cerebral artery after cerebral ischemia. Eur J Neurol 2006;13:1324-1332.
27. B receptor up-regulation after organ culture of rat mesenteric artery. Eur J Pharmacol 2003;482:39-47.
28. Henriksson M, Xu CB, Edvinsson L: Importance of ERK1/2 in upregulation of endothelin type B receptors in cerebral arteries. Br J Pharmacol 2004;142:1155-1161.
29. De Clerck F, Janssen PA:5-Hydroxytryptamine and thromboxane A2 in ischaemic heart disease. Blood Coagul Fibrinolysis 1990;1:201-209.
30. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
31. Karin M: Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs. Ann Rheum Dis 2004;63(suppl 2):ii62-ii64.
32. Surh YJ, Na HK, Lee SS: Transcription factors and mitogen-activated protein kinases as molecular targets for chemoprevention with anti-inflammatory phytochemicals. Biofactors 2004;21:103-108.
33. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-27494.
34. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-18632.
35. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC: SB 203580 is a specific inhibitor of a map kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995;364:229-233.
36. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE: SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 2000;293:281-288.
37. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001;98:13681-13686.
38. Kobori M, Yang Z, Gong D, Heissmeyer V, Zhu H, Jung YK, Gakidis MA, Rao A, Sekine T, Ikegami F, Yuan C, Yuan J: Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ 2004;11:123-130.
39. Malmsten C: Some biological effects of prostaglandin endoperoxide analogs. Life Sci 1976;18:169-176.
40. Lumley P, White BP, Humphrey PP: GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol 1989;97:783-794.
41. He GW, Yang CQ: Inhibition of vasoconstriction by the thromboxane A2 antagonist GR32191B in the human radial artery. Br J Clin Pharmacol 1999;48:207-215.
42. Black JW, Leff P: Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 1983;220:141-162.
43. Poliseno L, Cecchettini A, Mariani L, Evangelista M, Ricci F, Giorgi F, Citti L, Rainaldi G: Resting smooth muscle cells as a model for studying vascular cell activation. Tissue Cell 2006;38:111-120.
44. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-183.
45. B receptor alterations after cerebral ischaemia. Exp Brain Res 2007;178:470-476.
46. 1A- adrenoceptors in rat mesenteric artery involves intracellular signal pathways. Basic Clin Pharmacol Toxicol 2006;98:61-67.
47. B receptor mRNA expression and contraction during organ culture of rat mesenteric artery. Eur J Pharmacol 2002;452:215-222.
48. Henriksson M, Stenman E, Edvinsson L: Intracellular pathways involved in upregulation of vascular endothelin type B receptors in cerebral arteries of the rat. Stroke 2003;34:1479-1483.
49. Jamali R, Edvinsson L: Involvement of protein kinases on the upregulation of endothelin receptors in rat basilar and mesenteric arteries. Exp Biol Med (Maywood) 2006;231:403-411.
50. Thorne GD, Hilliard GM, Paul RJ: Vascular oxygen sensing: detection of novel candidates by proteomics and organ culture. J Appl Physiol 2004;96:802-808; discussion 792.
51. B receptor-mediated contraction requires phosphorylation of ERK1/2 proteins. Eur J Pharmacol 2006;538:124-131.
52. Dusting GJ, Mullins EM, Nolan RD: Prostacyclin (PGI2) release accompanying angiotensin conversion in rat mesenteric vasculature. Eur J Pharmacol 1981;70:129-137.
53. Bucher M, Hobbhahn J, Kurtz A: Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis. Crit Care Med 2001;29:1750-1755.
54. Zhang Y, Adner M, Cardell LO: Interleukin-1β attenuates endothelin B receptor-mediated airway contractions in a murine in vitro model of asthma: roles of endothelin converting enzyme and mitogen-activated protein kinase pathways. Clin Exp Allergy 2004;34:1480-1487.
55. Parent JL, Labrecque P, Orsini MJ, Benovic JL: Internalization of the TXA2 receptor α and β isoforms: role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J Biol Chem 1999;274:8941-8948.
56. Laroche G, Rochdi MD, Laporte SA, Parent JL: Involvement of actin in agonist-induced endocytosis of the G protein-coupled receptor for thromboxane A2: overcoming of actin disruption by arrestin-3 but not arrestin-2. J Biol Chem 2005;280:23215-23224.
57. 2 receptor expression by lipid soluble smoking particles through post-transcriptional mechanisms. Atherosclerosis 2008;196:608-616.
58. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd: Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med 1988;319:689-698.
59. Castellani S, Paladini B, Paniccia R, Di Serio C, Vallotti B, Ungar A, Fumagalli S, Cantini C, Poggesi L, Neri Serneri GG: Increased renal formation of thromboxane A2 and prostaglandin F2α in heart failure. Am Heart J 1997;133:94-100.
60. 2 and expression of procoagulant activity by monocytes in response to arachidonic acid in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 2001;65:133-138.